ACW Stock Overview
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Actinogen Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.028 |
| 52 Week High | AU$0.099 |
| 52 Week Low | AU$0.02 |
| Beta | 1.26 |
| 1 Month Change | 21.74% |
| 3 Month Change | -9.68% |
| 1 Year Change | 21.74% |
| 3 Year Change | -78.46% |
| 5 Year Change | -17.64% |
| Change since IPO | -96.59% |
Recent News & Updates
Recent updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Apr 30
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Nov 16Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Aug 02We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth
Apr 12We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely
Nov 28Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Aug 09Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Apr 07We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn
Oct 24Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business
Jul 11We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow
Mar 27How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?
Jan 07
Shareholder Returns
| ACW | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -9.7% | -1.4% | -2.3% |
| 1Y | 21.7% | 3.7% | 10.0% |
Return vs Industry: ACW exceeded the Australian Biotechs industry which returned 3.7% over the past year.
Return vs Market: ACW exceeded the Australian Market which returned 10% over the past year.
Price Volatility
| ACW volatility | |
|---|---|
| ACW Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: ACW has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ACW's weekly volatility has decreased from 22% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Steve Gourlay | actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
| ACW fundamental statistics | |
|---|---|
| Market cap | AU$79.91m |
| Earnings (TTM) | -AU$13.04m |
| Revenue (TTM) | AU$9.93m |
8.7x
P/S Ratio-6.6x
P/E RatioIs ACW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACW income statement (TTM) | |
|---|---|
| Revenue | AU$9.93m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$9.93m |
| Other Expenses | AU$22.98m |
| Earnings | -AU$13.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0042 |
| Gross Margin | 100.00% |
| Net Profit Margin | -131.34% |
| Debt/Equity Ratio | 0% |
How did ACW perform over the long term?
See historical performance and comparison